Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Operating Expenses (2016 - 2025)

IGC Pharma (IGC) has disclosed Operating Expenses for 16 consecutive years, with $3.0 million as the latest value for Q3 2025.

  • Quarterly Operating Expenses rose 53.12% to $3.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 million through Sep 2025, down 14.09% year-over-year, with the annual reading at $8.1 million for FY2025, 23.61% down from the prior year.
  • Operating Expenses for Q3 2025 was $3.0 million at IGC Pharma, up from $2.1 million in the prior quarter.
  • The five-year high for Operating Expenses was $6.6 million in Q1 2022, with the low at $1.6 million in Q1 2025.
  • Average Operating Expenses over 5 years is $2.9 million, with a median of $2.6 million recorded in 2024.
  • The sharpest move saw Operating Expenses surged 157.7% in 2021, then plummeted 42.82% in 2024.
  • Over 5 years, Operating Expenses stood at $2.4 million in 2021, then fell by 2.74% to $2.4 million in 2022, then skyrocketed by 31.55% to $3.1 million in 2023, then tumbled by 36.7% to $2.0 million in 2024, then soared by 51.26% to $3.0 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $3.0 million, $2.1 million, and $1.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.